AVA6207 Overcomes Topoisomerase I Inhibitor Resistance In Vitro and In Vivo with Robust and Tumor-Selective Release of Dual Exatecan and ATR inhibitor Payloads

On November 19, 2026 Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, reported the presentation of new preclinical data showing that AVA6207, a Next-Generation pre|CISION dual payload peptide-drug conjugate (PDC), reversed topoisomerase 1 inhibitor (TOP1i) resistance in vitro and in animal models with TOP1i-resistant tumors. The Company is presenting these studies today at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AVA6207 uses the Company’s pre|CISION PDC controlled-release technology to deliver exatecan, a potent TOP1i, and the ataxia telangiectasia and Rad3-related kinase inhibitor (ATRi) berzosertib directly to tumor cells in a single molecule to overcome resistance to TOP1i. Exatecan induces severe single strand breaks in DNA, triggering the DNA damage response (DDR) pathway. Berzosertib, an ATRi, potentiates the effect of TOP1i by blocking the DDR pathway to prevent cancer cells from repairing TOP1i-induced damage.

Avacta is the first company to develop a PDC capable of delivering two payloads directly to the tumor via a single, tumor-specific cleavage event. This single pre|CISION PDC medicine delivers both payloads directly to the tumor microenvironment via fibroblast activation protein (FAP) cleavage and holds tremendous potential to improve outcomes in the growing population of patients that are resistant to TOP1i.

Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said:

"Resistance to the topoisomerase 1 inhibitor drug class is one of the biggest barriers to better outcomes with this important class of cancer drugs, which includes an expanding pipeline of TOP1i ADCs. AVA6207 was designed to address this clinical challenge.

"What is striking about the data presented is that AVA6207 goes beyond simply restoring sensitivity in these resistant tumors. The complete responses observed in SLFN11-low and ATM-low PDX models, taken together with the remarkable consistency across the datasets for all our pre|CISION medicines including AVA6103 and AVA6000, give the Board increasing confidence as we move the dual payload program towards clinical development in these biomarker-defined groups of patients where AVA6207 can have the greatest impact. The consistency of these datasets across our pipeline also enables our multiple different levers to generate the capital investment needed to move these exciting programs forward in the clinic."

AVA6207 Preclinical Results

The preclinical studies presented today investigated two potential mechanisms through which AVA6207 could target cancers that are resistant or less responsive to TOP1i treatment: (1) resistance to TOP1i associated with Schlafen family member 11 (SLFN11) through SLFN11 loss and (2) synthetic lethality with ataxia telangiectasia mutated (ATM) loss. Importantly, both Rad3-related kinase (ATR) and ATM participate in sensing DNA damage following therapy with cytotoxic agents and both populations are shown here to have sensitivity to the combination of exatecan and berzosertib.

Both mechanisms independently leave tumors dependent on ATR kinase for survival, the exact vulnerability AVA6207 is designed to exploit. In SLFN11-deficient cells, AVA6207 reversed TOP1i resistance, forcing resistant cells into fatal mitotic catastrophe leading to cell death. ATM-deficient cells had approximately tenfold higher sensitivity to AVA6207 compared with wild-type or ATM-positive cells, while cell killing and immunofluorescence assays demonstrated the compound is capable of inducing synthetic lethality.

The in vivo patient-derived xenograft (PDX) models demonstrate the robust activity of AVA6207 in both ATM-low/SLFN11-low non-small cell lung cancer (NSCLC) and ATM+/SLFN11 low ovarian cancer; AVA6207 achieved complete responses in all animals with ovarian tumors and four of five with NSCLC tumors. In addition to the resistant models, AVA6207 also demonstrated superiority to the marketed antibody-drug conjugate (ADC) Enhertu in a gastric PDX model.

SLFN11-low and ATM-deficient tumors represent patient populations with high unmet need and are more likely to be vulnerable to synthetic lethality, enabling a biomarker-defined enrolment and enrichment strategy for the upcoming clinical development of AVA6207. The Company is evaluating clinical indications to identify biomarker-defined populations potentially suited to AVA6207, including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), ovarian cancer and esophageal squamous cell cancer (ESCC). The addressable markets across US, EU5 and Japan in these tumor types have an annual incidence that ranges from ~150,000-250,000 in NSCLC to the more rare, orphan subsets in ESCC numbering 4,000-20,000.

The presentation can be found on the Avacta Therapeutics publications page: Publications | Avacta Therapeutics

Details of the presentation

Title: AVA6207 is a novel pre|CISION technology compound delivering complementary TOP1i and ATRi payloads to the tumor microenvironment following FAP cleavage

Authors: Victoria Juskaite, Tom Clough, Ellen Watts, et al. and David Jones

Session Title: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)

Session Date and Time: Thursday, November 19, 09:00-17:30

Location: Exhibition Hall, Poster Area

Abstract Number: 161

(Press release, Avacta Life Sciences, NOV 19, 2026, View Source [SID1234674998])

Evaxion announces strategy and business update and third quarter 2026 financial results

On November 19, 2026 Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology platform, reported strategy and business update and announces third quarter 2026 financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Strategy update
Evaxion is refocusing its strategy to prioritize its immuno-oncology assets and capabilities, fully leveraging AI-Immunology in novel cancer target discovery and cancer vaccine development.

The aim is to maximize the value given clinical validation of the platform in personalized cancer vaccines with EVX-01 and the broader opportunity with off-the-shelf cancer vaccines in multiple indications through access to a wider diversity of novel antigens, including but not limited to endogenous retroviruses (ERVs).

Going forward, Evaxion will focus its R&D portfolio by:

Advancing off-the-shelf cancer vaccines EVX-04 and EVX-05 towards clinical development
Expanding personalized cancer vaccine EVX-01’s potential in multiple indications via partnerships
Continuing to identify new cancer vaccine targets for further development by mining novel sources from the dark genome
Working through partnerships on our preclinical portfolio of infectious disease assets
Completing validation on the autoimmune concepts we have developed with AI-Immunology for future partnerships
As a result of the refocused strategy, Evaxion will make some adjustments to its organization.

"We are refocusing our strategy on the unique capabilities of AI-Immunology in discovery and design of novel cancer vaccines. Evaxion’s AI-Immunology platform has recently been further validated by stronger clinical and translational datasets from the phase 2 trial with EVX-01 in advanced melanoma at a time when the entire landscape around personalized cancer vaccines has changed more positively. With the ability to also produce off-the-shelf cancer vaccines, we are maintaining strong operational momentum on all of our milestones for the year, tracking towards achieving the last one with the EVX-04 off-the-shelf vaccine clinical trial submission, as we re-focus our efforts towards immuno-oncology", says Helen Tayton-Martin, CEO of Evaxion.

Business highlights (since last quarterly update)

Presentation of three-year clinical outcome and immune data for personalized cancer vaccine EVX-01 at the ESMO (Free ESMO Whitepaper) Congress 2026 and additionally new phase 2 biomarker data at SITC (Free SITC Whitepaper) 2026
Announcing the upcoming presentation of new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the ASH (Free ASH Whitepaper) 2026 Meeting
Winning the 2026 International Prix Galien Award for Best digital health solution for AI-Immunology
Our cash runway has been extended towards the end of 2027
Conference call and webcast
Evaxion’s executive management will host a conference call and webcast at 8.30am ET/14.30 CET today, presenting the business update and financial results as well as taking questions.

To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.

To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.

Research & Development (R&D) update
Evaxion has a R&D pipeline of innovative vaccine candidates for both cancer and infectious diseases and has recently made progress in both areas.

Most notably, we have presented new phase 2 data for personalized cancer vaccine EVX-01, our most advanced pipeline asset, at both the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) and Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) congresses.

Designed with our AI-Immunology platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system to attack the cancer by mounting a targeted response against tumor-specific neoantigens.

EVX-01 is intended for first-line treatment of multiple advanced solid cancer tumors and has, in the phase 2 trial, been evaluated as a treatment of advanced melanoma. The recent data shows an 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up.

The very high precision rate is another confirmation that AI-Immunology identifies and selects the most therapeutically relevant vaccine targets. Thus, the new data supports both EVX-01 as a promising personalized cancer vaccine and AI-Immunology as a validated technology for discovery and design of novel cancer treatments.

Further to the personalized approach, we are leveraging AI-Immunology to develop novel off-the-shelf cancer vaccines, including EVX-04 targeting AML. Developed with AI-Immunology, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.

We are on track to file the application for a phase 1 trial with EVX-04 before the end of the year and continue to advance preclinical IND-enabling studies and expand the data package. We are very much looking forward to presenting new target validation data for EVX-04 at the important American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition in New Orleans, Louisiana, December 12-15, 2026.

Within infectious diseases we have achieved the milestone of designing and preclinically validating antigens to be included in EVX-B4, a novel vaccine candidate for Group A Streptococcus. As per our refocused strategy, we will only conduct future work on our infectious disease programs if funded by external partners and will continue to proactively pursue relevant partnership opportunities.

We have also recently presented AI-Immunology derived novel therapeutic concepts for autoimmune diseases. Our future activities in this space will be focused on concept validation for potential future partnerships.

Business development update
We remain active in multiple parallel partnership discussions based on external interest in both AI-Immunology and our R&D pipeline based on the strong clinical validation of our platform and as we continue to pursue our strategy of developing novel IO assets and strengthening our platform through strategic partnerships.

We were honored to receive the prestigious International Prix Galien Award for AI-Immunology as best digital health solution in October. The award is another strong external validation and recognition of the AI-Immunology platform in generating key data confirming the fact that AI-Immunology is a platform that delivers meaningful therapeutic product candidates. This is an important distinction with potential business partners.

Third quarter 2026 financial results
We have extended our cash runway towards the end of 2027 through utilization of our At-The-Market (ATM) equity program selling Evaxion shares resulting in gross proceeds of $2.2 million improving our cash at hand and equity.

Earlier in November, we filed an amendment to the registration statement on Form F-1 related to the 2025 debt settlement agreement with The European Investment Bank (EIB) with the US Securities and Exchange Commission.

The registration statement was originally filed in November 2025, as required under the agreement under which EIB converted debt to warrants, and relates solely to the possible resale by EIB of shares issuable upon exercise of those warrants. We are not conducting a capital raise.

The financial results for the third quarter 2026 were in line with expectations with a net loss of $3.5 million, compared to loss of $3.7 million in the second quarter 2026 and a profit of $4.6 million in the third quarter 2025.

Compared to same period last year where we recorded revenue from out-licensing EVX-B3 to MSD, no revenue has been recorded in Q3 2026, while we have reduced cost in the quarter compared to last year primarily relating to lower personnel expenses and capital market costs, and our net financial expenses reflects normalized financial income and expenses.

Research and development (R&D) expenses were $2.3 million for the third quarter 2026, aligned with second quarter 2026, and a reduction compared to third quarter last year, mainly due to reduced headcount.

General and administrative (G&A) expenses were $1.4 million for the quarter, level with second quarter 2026, and compared to $1.4 million in second quarter 2025. Compared to last year we have lower capital market cost compensated by higher business development costs.

Net financial expense of $0.1 million for the third quarter 2026 compared to net financial income of $1.3 million same quarter last year. The third quarter 2026 reflects our normalized business, and where Q3 last year was impacted by financial income from debt settlement agreement with EIB and financial expenses from a significant higher derivative liability.

Cash and cash equivalents as of September 30, 2026, were $13.3 million, compared to $14.0 million as of June 30, 2026, extending our current cash runway towards the end of 2027.

Total equity amounts to $8.1 million as of September 30, 2026, reflecting the net loss of the first nine months of 2026 and added the proceeds from ATM sales, when compared to $17.0 million as of December 31, 2025.

Evaxion A/S
(Unaudited) Consolidated statement of financial position data
(USD in thousands)

Sep 30,
2026 Dec 31,
2025
Cash and cash equivalents 13,274 23,234
Total assets 18,665 28,408
Total liabilities 10,523 11,369
Share capital 17,129 15,791
Other reserves 130,301 127,492
Accumulated deficit (139,288) (126,244)
Total equity 8,143 17,039
Total liabilities and equity 18,665 28,408

Evaxion A/S
(Unaudited) Consolidated statement of comprehensive loss data
(USD in thousands, except per share data)

Three Months Ended
Sep 30, Nine Months Ended
Sep 30,
2026 2025 2026 2025
Revenue - 7,492 - 7,528
Research and development (2,312) (3,092) (6,943) (7,415)
General and administrative (1,361) (1,377) (4,394) (5,295)
Operating profit/(loss) (3,673) 3,022 (11,338) (5,182)
Finance income 152 2,690 557 5,729
Finance expenses (212) (1,360) (730) (2,988)
Net profit/(loss) before tax (3,732) 4,352 (11,511) (2,442)
Income tax benefit 191 265 611 652
Net profit/(loss) for the period (3,541) 4,618 (10,899) (1,789)
Net loss attributable to shareholders of Evaxion A/S (3,541) 4,618 (10,899) (1,789)
Loss per share – basic and diluted (0.01) 0.01 (0.03) (0.01)
Number of shares used for calculation (basic and diluted) 431,856,012 318,041,649 422,013,554 289,792,967

(Press release, Evaxion, NOV 19, 2026, View Source [SID1234675022])

Nykode Therapeutics to Showcase APC-Targeted DNA Vaccine Platform at 3rd Annual Personalized Cancer Vaccine Summit

On November 19, 2026 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of cancer vaccines, reported that Chief Executive Officer, Michael Engsig, and Chief Scientific Officer and Co-founder, Agnete Fredriksen, will participate in the 3rd Annual Personalized Cancer Vaccine Summit, taking place December 1–3, 2026 in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nykode’s leadership will contribute to three sessions during the summit, sharing the company’s perspectives on the development, manufacturing, and clinical translation of personalized cancer vaccines.

"As interest in the field of individualized neoantigen cancer vaccines continues to grow, attention is increasingly turning to how these treatments can be delivered to patients at scale," said Agnete Fredriksen, Chief Scientific Officer and Co-founder of Nykode Therapeutics. "We believe our APCtargeted DNA platform offers a differentiated approach, supported by encouraging clinical immunogenicity data and an established manufacturing process. We look forward to contributing to discussions on the opportunities and challenges shaping the future of personalized cancer vaccines."

Nykode’s work in personalized cancer vaccines is being advanced through VB10.NEO, its wholly owned, DNA-based individualized neoantigen therapy (INT). Built on Nykode’s proprietary antigenpresenting cell (APC)-targeting technology and NeoSELECT, its AI-driven neoantigen selection engine, VB10.NEO is designed to deliver selected antigens to APCs to generate broad, potent, and long-lasting antigen-specific immune responses.

The company has established an end-to-end manufacturing process for VB10.NEO, achieving 100% manufacturing success across two clinical trials. Further optimization of the manufacturing process reduces the current turnaround-time from biopsy to product release to less than six weeks with a clear path to further reductions by additional consolidation under "one roof". Its plasmid DNA-based platform also offers potential advantages in manufacturing complexity, and cost of goods compared with alternative approaches.

Clinical data across two trials in patients with advanced solid tumors have demonstrated vaccinespecific immune responses in 88–100% of patients, including de novo T-cell responses in 85% of patients. These responses remained durable for more than one year after the final dose, supporting the potential of Nykode’s platform to generate strong and sustained immune responses.

Summit Program and Presentation Details

1. Workshop: Streamlining Manufacturing, Analytics & Supply Chain Operations to Accelerate
Delivery of Personalized Cancer Vaccines
Speaker: Michael Engsig
Date: Tuesday, December 1, 2026
Time: 9:00 a.m.

2. Seminar: From Promise to Practice: Enabling the Next Generation of Personalized Cancer
Vaccines
Speaker: Agnete Fredriksen
Date: Thursday, December 3, 2026
Time: 9:00 a.m

3. Panel Discussion: Comparing Personalized vs. Off-the-Shelf Cancer Vaccines to Choose
the Right Strategy for the Right Indication
Panelist: Agnete Fredriksen
Date: Thursday, December 3, 2026
Time: 11:30 a.m.

(Press release, Nykode Therapeutics, NOV 19, 2026, View Source [SID1234675038])

Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers

On November 19, 2026 AstraZeneca reported that Biologics License Application (BLA) for sonesitatug vedotin (Sone-Ve) has been accepted and granted Priority Review in the US for the 2nd and later-line treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or oesophageal adenocarcinoma (EAC) with Claudin 18.2 (CLDN18.2) expression on at least 25% of tumour cells at any staining intensity.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.1 The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the second quarter of 2027.

CLDN18.2 has emerged as an important therapeutic target for these patients, with an estimated 60% of gastric/GEJ cancers expressing CLDN18.2 in 25% or more of tumour cells.2 Each year, there are roughly 7,500 patients in the US treated in the 2nd and later-line setting for advanced or metastatic CLDN18.2-positive, non-HER2-positive gastric/GEJ cancers.3 The majority of patients with gastric/GEJ cancers are diagnosed at an advanced or metastatic stage, where the prognosis is especially poor and treatment options are limited.4 Less than 20% of patients diagnosed at this late-stage survive more than one year.5

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: "After progressing on first-line treatment, patients with Claudin 18.2-positive advanced gastric cancer have no targeted options. Sone-Ve is the first ADC targeting Claudin 18.2 to improve overall survival for patients compared to current standard of care in this setting and across a population that encompasses a much broader definition of Claudin 18.2 positivity than for current drugs. This Priority Review of our submission speaks to the significant potential of this medicine and accelerates the ability to bring forward a new targeted approach and alternative to traditional chemotherapy for thousands of patients in the US."

The BLA is based on results from the CLARITY-Gastric01 Phase III trial which were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper).

In the trial, Sone-Ve reduced the risk of death by 42% compared to investigator’s choice of therapy (based on an OS hazard ratio [HR] of 0.58; 95% confidence interval [CI] 0.47–0.73; p=0.000004) in the 2nd- and later line setting. Median OS was 10.6 months for patients treated with Sone-Ve compared to 6.4 months for investigator’s choice of therapy. The OS benefit observed was consistent across most predefined subgroups, including subgroups based on lower or higher CLDN18.2 expression levels.6

The tolerability profile of Sone-Ve was manageable and consistent with its known safety profile with no new safety signals identified. Fewer Grade 3 or higher treatment-related adverse events.6

Sone-Ve has received Orphan Drug Designation from the US Food and Drug Administration and the European Commission for the treatment of gastric and GEJ cancers. It has also received Breakthrough Designation in China for the 2nd-line treatment of gastric cancer. Regulatory applications are currently under review in the EU, China and several other countries based on the CLARITY-Gastric01 results.

Notes

Gastric and GEJ cancers
Gastric (stomach) cancer is the fifth most common cancer worldwide and the fifth-leading cause of cancer-related death.7 Nearly one million new patients were diagnosed with gastric cancer in 2024, with approximately 650,000 deaths reported globally. In many regions, its incidence has been increasing in patients younger than 50 years old, along with other gastrointestinal (GI) malignancies.7

GEJ cancer is a type of gastric cancer that arises from and spans the area where the oesophagus connects to the stomach.8

Most advanced gastric cancer patients will eventually experience disease progression after standard 1st-line therapies, and subsequent lines yield poor outcomes, with median survival of 5-10 months for patients receiving 2nd and later-line systemic treatments.9-11

Each year, there are roughly 183,500 patients in the US, EU, China and Japan treated in the 2nd and later-line setting for advanced or metastatic CLDN18.2-positive, non-HER2-positive gastric/GEJ cancers.3

CLARITY-Gastric01
CLARITY-Gastric01 is a randomised, open-label, sponsor-blinded, multicentre, global Phase III trial evaluating Sone-Ve as a 2nd and later-line therapy for patients with advanced or metastatic gastric cancer, GEJ cancer or EAC with CLDN18.2 expression in 25% or more of tumour cells, with IHC+ of any intensity. In the trial, patients were randomised 1:1:1 in Stage 1 (dose selection) to Sone-Ve monotherapy 2.2mg/kg or 1.8mg/kg every three weeks, or investigator’s choice of therapy (including regionally accepted chemotherapies or targeted therapies), the comparator arm. In Stage 2, the trial continued with Sone-Ve 2.2mg/kg as the recommended Phase III dose.

The efficacy analyses from this study will also provide the basis to evaluate the clinical performance of the Ventana SP455 assay for the identification of patients with advanced or metastatic gastric, GEJ or EAC cancers expressing CLDN18.2 who may benefit from Sone-Ve.

The trial is being conducted in 175 centres across 19 countries, including in North America, Europe, South America and Asia. Its dual primary endpoints are progression-free survival as assessed by blinded independent central review in the 2nd and later-line setting and OS in the 3rd and later-line setting. A key secondary endpoint is OS in the 2nd and later-line setting.

Sonesitatug Vedotin (Sone-Ve)
Sone-Ve is a novel investigational antibody drug conjugate (ADC) targeting CLDN18.2, a protein found in the stomach lining and a validated therapeutic target in oncology, particularly for GI cancers. Sone-Ve consists of an anti-CLDN18.2 monoclonal antibody, a protease-degradable linker and a cytotoxic small molecule MMAE payload.

AstraZeneca entered into a global exclusive licence agreement with KYM Biosciences to develop and commercialise Sone-Ve in March 2023. The Company recently announced a clinical collaboration agreement with Summit Therapeutics to evaluate Sone-Ve in combination with ivonescimab, a first-in-class PD-1/VEGF bispecific, in GI cancers.

In addition to CLARITY-Gastric01, Sone-Ve is being evaluated in the CLARITY-Gastric02 Phase III trial in combination with capecitabine, with or without rilvegostomig, as a 1st-line treatment for advanced or metastatic gastric cancer, GEJ cancer and EAC. In Phase II development, Sone-Ve is being evaluated in patients with advanced solid tumours in multiple combinations across settings, including in CLDN18.2-positive pancreatic and biliary tract cancer (BTC).

(Press release, AstraZeneca, NOV 19, 2026, View Source [SID1234674999])

DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors

On November 19, 2026 DISCO Pharmaceuticals ("DISCO") reported a strategic collaboration and option-to-license agreement with AbbVie to discover and develop novel AND-gated bispecific therapeutics for solid tumors with high unmet medical need.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, DISCO will receive $40 million in upfront payments and is eligible for up to $2.5 billion in option, development, and other milestone payments, plus tiered royalties on worldwide net sales.

"The collaboration with AbbVie represents an important opportunity to deliver the next generation of precision medicines to patients with difficult-to-treat solid tumors," said Mark Manfredi, Ph.D., CEO of DISCO Pharmaceuticals. "Our AND-gated approach is designed to selectively target tumor cells while sparing healthy tissue, thus offering a potentially differentiated path in precision oncology. Our DISCOtech platform’s unique ability to identify tumor-selective target pairs provides the foundation for therapies with the potential for a wider therapeutic window."

"We look forward to working together with AbbVie towards the shared goal of creating transformative therapeutics for patients. This collaboration further underscores the potential of our differentiated platform and complements our portfolio of internal and partnered pipeline programs," added Ajla Hrle, Ph.D., CBO of DISCO Pharmaceuticals.

(Press release, DISCO Pharmaceuticals, NOV 19, 2026, View Source [SID1234675023])